CAR T-Cell Therapy in Lymphomas
CAR T-Cell Therapy for Myeloma
CAR T-Cell Therapies for R/R ALL
Best Practices in Identifying and Managing CAR T-Cell–Mediated Toxicities
Renier J. Brentjens, MD, PhD
Department of Medicine
Weill Medical College of Cornell University
Department of Pharmacology
Weill Cornell Graduate School of Medical Sciences
Department of Medicine
Memorial Sloan Kettering Cancer Center
New York, New York
Frederick L. Locke, MD
Co-Leader, Moffitt Immuno-Oncology Program
Vice Chair and Associate Member
Department of Blood and Marrow Transplant and Cellular Immunotherapy
Immune Cell Therapy Program
Blood and Marrow Transplant and Cellular Immunotherapy
Moffitt Cancer Center
The goal of this activity is to improve the knowledge, competence, and performance of physicians and other healthcare providers so they can confidently and competently integrate CAR T-cell therapy into their clinical practices.
This program is intended for physicians and other healthcare providers who treat and manage patients with leukemia, lymphoma, or myeloma who are candidates for CAR T-cell therapies.
At the conclusion of this activity, learners should be able to:
- Review the biologic principles underlying CAR T-cell therapy, structure and function of the CAR, and the mechanism of action of CAR T-cells
- Identify characteristics of patients who are appropriate for treatment with CAR T-cell therapy
- Integrate into practice clinical trial data on CAR T-cell–based therapies for the treatment of patients with leukemia and lymphoma
- Evaluate emerging clinical data and novel approaches to CAR T-cell therapy for patients with myeloma
- Based on the current best evidence, implement strategies for managing toxicities associated with CAR T-cell therapy
- Recall ongoing clinical trials evaluating CAR T-cell therapy for the treatment of leukemia, lymphoma, and myeloma to aid in the referral of appropriate patients
Joint Accreditation Statement
In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
Physician Continuing Medical Education
CCO designates this live activity for a maximum of 3.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
American Board of Internal Medicine Maintenance of Certification
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 3.0 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
If you are interested in having us report ABIM MOC, please ensure the following information is provided within your CCO Member Profile:
Name - as registered with ABIM
Date of Birth (Month/Day)
Your ABIM ID number
Disclosure of Conflicts of Interest
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any relevant conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.